share_log

PacBio Expects To Reduce Non-GAAP Annualized Expense Run Rate By More Than $75M By End Of 2024 Vs. Initial Guidance Of 5% Growth In 2024 Operating Expenses

Benzinga ·  May 9 16:26

Initiated activities to reduce annualized run-rate operating expenses and the Company expects to achieve above the high end of previously provided range of non-GAAP reduction of $50 million to $75 million by the end of 2024 compared to prior guidance of 5% operating expense growth.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment